Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-21 06:10 am Purchase | 2023-02-21 | 13D | Evelo Biosciences, Inc. EVLO | DNCA FINANCE | 22 4.960% | 22 (New Position) | Filing History |
| 2022-11-21 08:28 am Sale | 2022-11-21 | 13D | Evelo Biosciences, Inc. EVLO | DNCA FINANCE | 0 0.000% | -46 (Position Closed) | Filing History |
| 2022-08-23 09:32 am Purchase | 2022-08-23 | 13D | Evelo Biosciences, Inc. EVLO | DNCA FINANCE | 46 3.630% | 12 (+33.72%) | Filing History |
| 2021-12-28 3:58 pm Purchase | 2021-12-28 | 13D | Evelo Biosciences, Inc. EVLO | DNCA FINANCE | 34 5.030% | 34 (New Position) | Filing History |
| 2020-03-06 11:13 am Purchase | 2020-03-06 | 13D | BioXcel Therapeutics, Inc. BTAI | DNCA FINANCE | 892,453 4.380% | 891,542 (+97864.11%) | Filing History |
| 2020-02-24 09:30 am Purchase | 2020-02-24 | 13D | BioXcel Therapeutics, Inc. BTAI | DNCA FINANCE | 911 5.050% | 31 (+3.52%) | Filing History |
| 2020-02-18 10:18 am Purchase | 2020-02-18 | 13D | BioXcel Therapeutics, Inc. BTAI | DNCA FINANCE | 880 4.880% | 80 (+10.00%) | Filing History |